Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is the a Difference Between Rehabilitation Treatment, Pelvic Floor Muscle Training, Bladder Training and Anticholinergic Drug Treatment in UUI in the Long Term: A Study of Impairment, Quality of Life, and Cost Effectiveness
Brief Summary: * Urinary Urge Incontinence (UUI) is the involuntary urine loss associated with a strong sensation to void.
* UUI usually associated with reduced bladder capacity.
* The pathophysiology is unclear.
* Pelvic floor muscle dysfunction and detrusor instability have been suggested as possible mechanisms.
* Standard treatment includes anticholinergic medication and behavior modification.
* The study aims to compare the long term effectiveness of 4 different approaches to the treatment of women with Urge Urinary Incontinence (UUI):

  1. Pelvic Floor Rehabilitation (includes muscle training+behavioral intervention+bladder training)
  2. Pelvic Floor muscle training alone
  3. Bladder Training alone
  4. Drug treatment with Tolterodine.
* Study variables will include: impairment ratings, quality of life, and cost-effectiveness.
* This study addresses three issues:

  1. The long term efficacy and cost-effectiveness of the various treatment options.
  2. To identify the factors involved in determining the effectiveness of drug or behavioral therapy.
  3. The pathophysiology of UUI. By subdividing the rehabilitation group into 3 arms, we hope to shed light on the mechanism of dysfunction. A better response in one group will help localize the problem to pelvic floor muscles or to detrusor instability.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: tolterodine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: bladder training | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pelvic floor muscle training | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pelvic floor rehabilitation | Intervention Type: PROCEDURE; Name: tolterodine; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: bladder training; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: pelvic floor muscle training; Assigned to Arm(s): 3 | Intervention Type: PROCEDURE; Name: pelvic floor rehabilitation; Assigned to Arm(s): 4
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Solifenacin 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: solifenacin | Arm Label: Solifenacin 10 mg; Type: EXPERIMENTAL; Interventions: Drug: solifenacin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Solifenacin 5 mg | Intervention Type: DRUG; Name: solifenacin; Assigned to Arm(s): Solifenacin 10 mg, Solifenacin 5 mg
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Mirabegron 25 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron | Arm Label: Mirabegron 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron | Arm Label: Solifenacin 2.5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin succinate | Arm Label: Solifenacin 5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin succinate | Arm Label: Solifenacin 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin succinate | Arm Label: Solifenacin 2.5 mg and Mirabegron 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Arm Label: Solifenacin 2.5 mg and Mirabegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Arm Label: Solifenacin 5 mg and Mirabegron 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Arm Label: Solifenacin 5 mg and Mirabegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Arm Label: Solifenacin 10 mg and Mirabegron 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Arm Label: Solifenacin 10 mg and Mirabegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Mirabegron, Drug: Solifenacin succinate | Intervention Type: DRUG; Name: Mirabegron; Assigned to Arm(s): Mirabegron 25 mg, Mirabegron 50 mg, Solifenacin 10 mg and Mirabegron 25 mg, Solifenacin 10 mg and Mirabegron 50 mg, Solifenacin 2.5 mg and Mirabegron 25 mg, Solifenacin 2.5 mg and Mirabegron 50 mg, Solifenacin 5 mg and Mirabegron 25 mg, Solifenacin 5 mg and Mirabegron 50 mg | Intervention Type: DRUG; Name: Solifenacin succinate; Assigned to Arm(s): Solifenacin 10 mg, Solifenacin 10 mg and Mirabegron 25 mg, Solifenacin 10 mg and Mirabegron 50 mg, Solifenacin 2.5 mg, Solifenacin 2.5 mg and Mirabegron 25 mg, Solifenacin 2.5 mg and Mirabegron 50 mg, Solifenacin 5 mg, Solifenacin 5 mg and Mirabegron 25 mg, Solifenacin 5 mg and Mirabegron 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: VESIcare® | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: VESIcare®; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: A